Noveome Biotherapeutics, Inc. to Present at 9th Annual Glaucoma 360 Meeting

About the Retinal and Optic Nerve Disease Clinical Programs
To date, all glaucoma treatments are aimed at lowering intraocular hypertension. Noveome’s multi-target platform biologic and lead product, ST266, is the first potential therapeutic focused on treating the underlying nerve degeneration that occurs in glaucoma through an innovative, non-invasive, targeted intranasal device to deliver ST266 directly to the retina and optic nerve by-passing the blood-brain barrier. Based on successful preclinical studies, Noveome is currently conducting a Phase 1 open-label clinical trial to establish the safety of ST266 by intranasal delivery with topline data expected in 2020.

About Noveome Biotherapeutics, Inc.
Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Its novel platform biologic, ST266, is currently being evaluated in multiple ophthalmic indications. In addition to the Phase 1 open label clinical trial to establish the safety of ST266 when delivered intranasally, Noveome is conducting a Phase 2 open-label clinical trial evaluating the efficacy of ST266 in healing Persistent Corneal Epithelial Defects (PEDs) when delivered topically to the eye with topline data expected in 2020. To date, Noveome has received over $160 million in research and infrastructure funding from Lancet Capital, the U.S. Department of Defense, the Commonwealth of Pennsylvania and Allegheny County. Noveome is based in Pittsburgh, PA. For more information, please visit, www.noveome.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005208/en/